In a meta-analysis of 42 studies, exposure to air pollutants and high temperatures was associated with higher risk for clinic ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

This new meta-analysis looked to better solidify connections between atopic dermatitis and environmental irritants, such as ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Galderma begins 2 new clinical trials to investigate efficacy and safety of nemolizumab to treat patients with systemic sclerosis: Zug, Switzerland Friday, June 27, 2025, 13:00 Hr ...

Vico, meanwhile, swears by photobiomodulation light therapy for “flare-ups, eczema, atopic dermatitis and acne”. In short, ...

There are several potential health benefits of figs, from promoting digestion and heart health to potentially managing blood ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.